Open Targets Platform Open Targets Platform: release 20.02 is out We have a new release of the Open Targets Platform: new ... ... more targets, more evidence and associations.
Q&A Getting to know intOGen, a resource for the identification of cancer driver genes Open Targets Q&A on identifying cancer driver genes and their mechanism of action with intOGen.
ontology EFO3: A community-driven ontology to advance clinical discoveries In the 19.11 release of the Open Targets Platform, we moved from EFO2 to EFO3. Here we explore what the new disease ontology means to Open Targets.
Open Targets Platform Using ChEMBL for target identification and prioritisation Open Targets Q&A on the identification of cancer driver genes and their mechanism of action using intOGen. Using ChEMBL for target identification and prioritisation
Open Targets Platform Open Targets Platform: release 19.11 is out We have a new release of the Open Targets Platform: new EFO3, FDA pharmacovigilance data, new chemical probes, more targets, more evidence and associations.
Open Targets Platform From antibody to zinc finger: an A-Z of Open Targets As scientists discover our freely available resources, it’s time to take a closer look at the terms that matter to Open Targets. November is time for H.
Open Targets Platform Open Targets Platform: release 19.09 is out We have a new release of the Open Targets Platform: more target-disease associations, more chemical probes and target enabling packages, and updated Elasticsearch.
Open Targets Platform On diseases and phenotypes, and how we learnt to stop worrying and ignore the distinction One of the questions that Open Targets Platform users ask is why we don't distinguish diseases from phenotypes. Ian Dunham tells us more in this blog post.
Open Targets From antibody to zinc finger: an A-Z of Open Targets As users discover our freely available resources, it’s time to take a closer look at the terms that matter to Open Targets. This time we have a double bill: F and G.
Open Targets Platform Open Targets Platform: release 19.06 is out We have a new release of the Open Targets Platform: more target safety information and new target-disease associations are some of the highlights in release 19.06.
Q&A Using CRISPR priority score to identify targets in cancer drug discovery Open Targets Q&A on the first set of CRISPR screen results in cancer for target identification and prioritisation in drug discovery.
Open Targets Platform Open Targets Platform: release 19.04 is out We have a new release of the Open Targets Platform: CRISPR-Cas9 data and target safety information are some of the highlights in release 19.04.
Q&A Avoiding confusion in disease biology with ontologies Open Targets Q&A on the importance of describing diseases with ontologies when searching for new therapeutic targets in drug discovery.
genetic associations Adding a data source to the Open Targets Platform: an update In this post, I will give you an update on how to add a new data source to the Open Targets Platform following parts 1 and 2 published in 2018.
Open Targets From antibody to zinc finger: an A-Z of Open Targets As users discover our freely available resources, it’s time to take a closer look at the terms that matter to Open Targets. March is time for E.
Open Targets Platform Open Targets Platform: release 19.02 is out Our latest release of the Open Targets Platform is out. We have more targets, more diseases, more evidence, more associations, and fixed some bugs too.
Open Targets Platform From antibody to zinc finger: an A-Z of Open Targets As users discover our freely available resources, it’s time to take a closer look at the terms that matter to Open Targets. It's D-time.
Open Targets Platform Open Targets Platform: release 18.12 is out Our latest release of the Open Targets Platform is out. New data source - systems biology, new target tractability visualisation and more non-coding RNA genes.
Open Targets Platform From antibody to zinc finger: an A-Z of Open Targets As users discover our freely available resources, it’s time to take a closer look at the terms that matter to Open Targets. Third in the series is C.
Open Targets Platform How to add a new data source to the Open Targets Platform, part 2 In this post, I will continue guiding you on how to add a new data source to the Open Targets Platform. This is part 2 of a 2-part series of posts.
genetic associations How to add a new data source to the Open Targets Platform - part 1 In this post, I will show you how to add a new data source to the Open Targets Platform. This is part 1 of a 2-part series of posts.
Open Targets Platform How to navigate the complexity of cancer genetics with the Cancer Gene Census Cancer is not a single disease, but a group of diseases underlined by extraordinary genetic complexity. How can cancer researchers navigate this complexity?
Open Targets From antibody to zinc finger: an A-Z of Open Targets As users discover our freely available resources, it’s time to take a closer look at the terms that matter to Open Targets. Second in the series is B.
release notes Open Targets Platform: what's new in our latest release Our latest release of the Open Targets Platform is out. More targets, more evidence, more target-disease associations and a new prioritisation view.
chemical probes Probing your next target? Use our Chemical Probes feature for target validation in Open Targets Chemical probes are powerful research reagents for preclinical target validation in drug development projects.
